Find clinical trials

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A (HA) without factor VIII (FVIII) inhibitors or with HA of any severity (severe, moderate, and mild) with FVIII inhibitors.

Study ALN-AGT01-008 (ZilebEsiraN CardIovascular OuTcome Study in Hypertension [ZENITH]) is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study designed to evaluate the efficacy and safety of zilebesiran, administered subcutaneously (SC), in adult patients with established CVD or high risk for CVD whose hypertension is not adequately controlled by at least 2 standard of care antihypertensive medications.  The primary objective of the study is to evaluate the efficacy of zilebesiran in patients with uncontrolled hypertension and with either established CVD or high risk for CVD by demonstrating the ability of zilebesiran to reduce the risk of CV death, nonfatal MI, nonfatal stroke, or HF events (hospitalization for HF or urgent HF visit). Secondary and exploratory objectives of the study include evaluating the effect of zilebesiran on additional clinical outcomes, blood pressure, and renal function. 

Study regarding the safety, tolerability and effectiveness of Zoely for menstrually related migraine